LEI 101 hydrochloride salt form · hydrochloride · Parent LEI 101 hydrochloride
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist.
For research use only. Not for human or veterinary use.
Target
Cannabinoid Receptor
Research area
Neurological Disease
Purity >98%
Stock Inquire
LEI 101 hydrochloride structure
CAS No.: 2250025-91-1
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 10 mg | USD 365.00 | BP-01997A-10mg | In stock | Get quote |
| 25 mg | USD 565.00 | BP-01997A-25mg | In stock | Get quote |
| 50 mg | USD 920.00 | BP-01997A-50mg | In stock | Get quote |
| 100 mg | USD 1,465.00 | BP-01997A-100mg | In stock | Get quote |
| 250 mg | Inquire | BP-01997A-250mg | Inquire | Inquire |
Need another size or custom synthesis? Request a quote.
Description
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors[1][2].
Identifiers
- SMILES
-
C1CC1N2C(=O)CN(C2=O)CC3=CC=C(C=C3)C4=NC(=C(C=C4)F)CN5CCS(=O)(=O)CC5.Cl - InChIKey
-
APLLNJWPLUIBCG-UHFFFAOYSA-N
Specifications
- MW (average)
- 508.9930
- Formula
- C23H26ClFN4O4S
- CAS No.
- 2250025-91-1
- Physical state
- Solid
- Color
- White to off-white
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20℃, sealed storage, away from moisture; In solvent -20℃, 1 month;
Solubility
soluble in DMSO
Documents
References
[1]. Mario van der Stelt, et al. Discovery and Optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione Derivatives as a Novel Class of Selective Cannabinoid CB2 Receptor Agonists. J Med Chem. 2011 Oct 27;54(20):7350-62.
[2]. Partha Mukhopadhyay, et al. The Novel, Orally Available and Peripherally Restricted Selective Cannabinoid CB2 Receptor Agonist LEI-101 Prevents Cisplatin-Induced Nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58.